Sugi Predict

Sugi Predict / Targets / KDM5A

KDM5A

Lysine-specific demethylase 5A · P29375 · KDM5A on Sugi Atlas →

67,966 patent compounds predicted against KDM5A, 32,698 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL280293 SCHEMBL280293 0.56 13/20
SCHEMBL211903 SCHEMBL211903 0.41 8/20
Amiodarone Amiodarone (SCHEMBL16284) 1.00 7/20
Amiodarone Amiodarone (SCHEMBL41348) 0.98 7/20
SCHEMBL365810 SCHEMBL365810 0.71 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL369126) 0.69 7/20
Amiodarone Amiodarone (SCHEMBL297474) 0.63 7/20
SCHEMBL168312 SCHEMBL168312 0.53 7/20
SCHEMBL353289 SCHEMBL353289 0.61 6/20
SCHEMBL65040 SCHEMBL65040 0.50 6/20
SCHEMBL283713 SCHEMBL283713 0.41 6/20
SCHEMBL103352 SCHEMBL103352 0.38 6/20
SCHEMBL214254 SCHEMBL214254 0.36 6/20
SCHEMBL103879 SCHEMBL103879 0.36 6/20
SCHEMBL215558 SCHEMBL215558 0.33 6/20
SCHEMBL163903 SCHEMBL163903 0.69 5/20
SCHEMBL278062 SCHEMBL278062 0.69 5/20
SCHEMBL195944 SCHEMBL195944 0.56 5/20
SCHEMBL195731 SCHEMBL195731 0.53 5/20
SCHEMBL254322 SCHEMBL254322 0.49 5/20

Clinical trials — most relevant to KDM5A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations PHASE2SUSPENDED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
The Danish TURNER Cryopreservation Study nanRECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KDM5A binder may also engage these)

ProteinNameSimilarity
KDM5B Lysine-specific demethylase 5B 1.000 landscape →
KDM5D Lysine-specific demethylase 5D 1.000 landscape →
Q3UXZ9 — 1.000 Q3UXZ9 →
Q5F3R2 — 1.000 Q5F3R2 →
Q62240 — 1.000 Q62240 →
Q5XUN4 — 1.000 Q5XUN4 →
P41230 — 1.000 P41230 →
Q30DN6 — 1.000 Q30DN6 →
Q80Y84 — 1.000 Q80Y84 →
Q6IQX0 — 0.999 Q6IQX0 →
A1YVX4 — 0.999 A1YVX4 →
KDM5C Lysine-specific demethylase 5C 0.995 landscape →
Q38JA7 — 0.994 Q38JA7 →
Q61T02 — 0.994 Q61T02 →
KAT8 Histone acetyltransferase KAT8 0.992 landscape →
Q5XI06 — 0.992 Q5XI06 →
Q8VIJ5 — 0.992 Q8VIJ5 →
DHX29 ATP-dependent RNA helicase DHX29 0.992 landscape →
F4I240 — 0.991 F4I240 →
Q7Z401 — 0.991 Q7Z401 →
Q9H1H9 — 0.991 Q9H1H9 →
Q9VMJ7 — 0.991 Q9VMJ7 →
Q8WUM0 — 0.991 Q8WUM0 →
Q2KI89 — 0.990 Q2KI89 →
A1L252 — 0.990 A1L252 →
Q6P158 — 0.990 Q6P158 →
INPP5B Type II inositol 1,4,5-trisphosphate 5-phosphatase 0.990 landscape →
F4IDQ6 — 0.990 F4IDQ6 →
A3KMI0 — 0.990 A3KMI0 →
Q9LSP8 — 0.990 Q9LSP8 →